BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30970129)

  • 1. Polymorphisms in the CIITA -168A/G (rs3087456) and CIITA +1614G/C (rs4774) may influence severity in multiple sclerosis patients.
    Pereira VCSR; Fontes-Dantas FL; Paradela ER; Malfetano FR; Scherpenhuijzen SSB; Mansur LF; Luiz RR; Oliveira AP; Farinhas JGD; Maiolino Â; Alves-Leon SV
    Arq Neuropsiquiatr; 2019 Mar; 77(3):166-173. PubMed ID: 30970129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CIITA variation in the presence of HLA-DRB1*1501 increases risk for multiple sclerosis.
    Bronson PG; Caillier S; Ramsay PP; McCauley JL; Zuvich RL; De Jager PL; Rioux JD; Ivinson AJ; Compston A; Hafler DA; Sawcer SJ; Pericak-Vance MA; Haines JL; ; Hauser SL; Oksenberg JR; Barcellos LF
    Hum Mol Genet; 2010 Jun; 19(11):2331-40. PubMed ID: 20211854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CIITA genetic polymorphism rs4774*C in combination with the HLA-DRB1*15:01 allele as a putative susceptibility factor to multiple sclerosis in Brazilian females.
    Paradela ER; Alves-Leon SV; Figueiredo AL; Pereira VC; Malfetano F; Mansur LF; Scherpenhuijzen S; Agostinho LA; Rocha CF; Rueda-Lopes F; Gasparetto E; Paiva CL
    Arq Neuropsiquiatr; 2015 Apr; 73(4):283-8. PubMed ID: 25992516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability in the CIITA gene interacts with HLA in multiple sclerosis.
    Gyllenberg A; Piehl F; Alfredsson L; Hillert J; Bomfim IL; Padyukov L; Orho-Melander M; Lindholm E; Landin-Olsson M; Lernmark Å; ; ; Olsson T; Kockum I
    Genes Immun; 2014; 15(3):162-7. PubMed ID: 24430172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ApaI, BsmI and TaqI VDR gene polymorphisms in association with multiple sclerosis in Slovaks.
    Čierny D; Michalik J; Škereňová M; Kantorová E; Sivák Š; Javor J; Kurča E; Dobrota D; Lehotský J
    Neurol Res; 2016 Aug; 38(8):678-84. PubMed ID: 27338176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.
    Guerrero AL; Laherrán E; Gutiérrez F; Martín-Polo J; Iglesias F; Alcázar C; Peralta J; Rostami P
    Acta Neurol Scand; 2008 Jan; 117(1):21-5. PubMed ID: 17883422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both qualitative and quantitative genetic variation of MHC class II molecules may influence susceptibility to autoimmune diseases: the case of endemic pemphigus foliaceus.
    Piovezan BZ; Petzl-Erler ML
    Hum Immunol; 2013 Sep; 74(9):1134-40. PubMed ID: 23777927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CIITA rs4774 and rs6498122 polymorphisms are associated with oral lichen planus in Chinese people: a case-control study.
    Wu D; Wang L; Sun M; Wang G; Fu S; Dong G; Wu Y
    Eur J Oral Sci; 2013 Apr; 121(2):69-75. PubMed ID: 23489895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of MHCIITA rs3087456 and rs4774 polymorphisms in the susceptibility to cardiovascular disease of patients with rheumatoid arthritis.
    Garcia-Bermudez M; González-Juanatey C; Lopez-Mejias R; Rodriguez-Rodriguez L; Pérez-Esteban S; Castañeda S; Urcelay E; Miranda-Filloy JA; Gómez-Vaquero C; Fernández-Gutierrez B; Balsa A; González-Alvaro I; Blanco R; Llorca J; Martín J; Gonzalez-Gay MA
    Clin Exp Rheumatol; 2012; 30(1):51-7. PubMed ID: 22272574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arylsulfatase a gene polymorphisms in relapsing remitting multiple sclerosis: genotype-phenotype correlation and estimation of disease progression.
    Baronica KB; Mlinac K; Ozretić D; Vladić A; Bognar SK
    Coll Antropol; 2011 Jan; 35 Suppl 1():11-6. PubMed ID: 21648305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MHC2TA-168A/G and +1614G/C polymorphisms and risk for multiple sclerosis or chronic inflammatory arthropathies.
    O'Doherty C; Hawkins S; Rooney M; Vandenbroeck K
    Tissue Antigens; 2007 Sep; 70(3):247-51. PubMed ID: 17661914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of association of the CIITA -168A→G promoter SNP with myasthenia gravis and its role in autoimmunity.
    Ramanujam R; Zhao Y; Pirskanen R; Hammarström L
    BMC Med Genet; 2010 Oct; 11():147. PubMed ID: 20942939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoimmune disease association signals in CIITA and KIAA0350 are not involved in celiac disease susceptibility.
    Dema B; Martínez A; Fernández-Arquero M; Maluenda C; Polanco I; Angeles Figueredo M; de la Concha EG; Urcelay E; Núñez C
    Tissue Antigens; 2009 Apr; 73(4):326-9. PubMed ID: 19317741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Link between CIITA rs3087456 polymorphism and the risk of laryngeal squamous cell carcinoma in a Chinese population.
    Xue Y; Tang D; Li SJ; Zhou J; Hsueh CY; Zhao DD; Heng Y; Tao L; Lu LM
    Pathol Res Pract; 2020 Jan; 216(1):152793. PubMed ID: 31870593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis.
    Sternberg Z; Leung C; Sternberg D; Yu J; Hojnacki D
    Cardiovasc Ther; 2014 Apr; 32(2):33-9. PubMed ID: 24119301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rs4774 CIITA missense variant is associated with risk of systemic lupus erythematosus.
    Bronson PG; Goldstein BA; Ramsay PP; Beckman KB; Noble JA; Lane JA; Seldin MF; Kelly JA; Harley JB; Moser KL; Gaffney PM; Behrens TW; Criswell LA; Barcellos LF
    Genes Immun; 2011 Dec; 12(8):667-71. PubMed ID: 21614020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders.
    Fragomeni MO; Bichuetti DB; Oliveira EML
    Mult Scler Relat Disord; 2018 Oct; 25():138-142. PubMed ID: 30075406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
    Johnson BH; Bonafede MM; Watson C
    CNS Drugs; 2015 Jun; 29(6):503-10. PubMed ID: 26113055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic association analysis of CIITA variations with nasal polyp pathogenesis in asthmatic patients.
    Bae JS; Pasaje CF; Park BL; Cheong HS; Kim JH; Uh ST; Park CS; Shin HD
    Mol Med Rep; 2013 Mar; 7(3):927-34. PubMed ID: 23292525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.